CRISPR Therapeutics AG (NASDAQ: CRSP) is -26.69% lower on its value in year-to-date trading and has touched a low of $37.55 and a high of $91.10 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The CRSP stock was last observed hovering at around $45.44 in the last trading session, with the day’s gains setting it 0.45%.
Currently trading at $45.89, the stock is -2.84% and -10.84% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.73 million and changing 0.99% at the moment leaves the stock -25.25% off its SMA200. CRSP registered -10.14% loss for a year compared to 6-month loss of -38.63%.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a -4.83% gain in the last 1 month and extending the period to 3 months gives it a -29.21%, and is 1.41% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 3.75% over the week and 3.85% over the month.
CRISPR Therapeutics AG (CRSP) has around 407 employees, a market worth around $3.91B and $202.23M in sales. Profit margin for the company is -131.44%. Distance from 52-week low is 22.21% and -49.63% from its 52-week high. The company has generated returns on investments over the last 12 months (-12.11%).
CRISPR Therapeutics AG quarterly earnings per share for the current quarter are estimated at -1.42 with sales reaching $7.06M over the same period.The EPS is expected to shrink by -188.67% this year, but quarterly earnings will post -86.60% year-over-year. Quarterly sales are estimated to shrink -11.30% in year-over-year returns.
602.0 institutions hold shares in CRISPR Therapeutics AG (CRSP), with institutional investors hold 72.80% of the company’s shares. The shares outstanding are 85.17M, and float is at 81.47M with Short Float at 21.41%. Institutions hold 71.54% of the Float.
The top institutional shareholder in the company is CAPITAL INTERNATIONAL INVESTORS with over 7.87 million shares valued at $424.8 million. The investor’s holdings represent 9.6159 of the CRSP Shares outstanding. As of 2024-06-30, the second largest holder is ARK INVESTMENT MANAGEMENT LLC with 7.78 million shares valued at $420.12 million to account for 9.5098 of the shares outstanding. The other top investors are SUMITOMO MITSUI TRUST HOLDINGS, INC. which holds 3.15 million shares representing 3.853 and valued at over $170.21 million, while NIKKO ASSET MANAGEMENT AMERICAS, INC. holds 3.853 of the shares totaling 3.15 million with a market value of $169.99 million.
CRISPR Therapeutics AG (CRSP) Insider Activity
The most recent transaction is an insider sale by Bruno Julianne, the company’s Chief Operating Officer. SEC filings show that Bruno Julianne sold 3,366 shares of the company’s common stock on Jun 21 ’24 at a price of $56.09 per share for a total of $0.19 million. Following the sale, the insider now owns 6745.0 shares.
CRISPR Therapeutics AG disclosed in a document filed with the SEC on Apr 15 ’24 that Kulkarni Samarth (Chief Executive Officer) sold a total of 19,582 shares of the company’s common stock. The trade occurred on Apr 15 ’24 and was made at $59.91 per share for $1.17 million. Following the transaction, the insider now directly holds 0.21 million shares of the CRSP stock.
Still, SEC filings show that on Mar 15 ’24, Prasad Raju (Chief Financial Officer) disposed off 3,524 shares at an average price of $72.69 for $0.26 million. The insider now directly holds 6,476 shares of CRISPR Therapeutics AG (CRSP).
